Published online Jan 15, 2019. doi: 10.5497/wjp.v8.i1.1
Peer-review started: September 23, 2018
First decision: November 5, 2018
Revised: November 17, 2018
Accepted: January 5, 2019
Article in press: January 5, 2019
Published online: January 15, 2019
Core tip: Flupirtine exhibits pharmacological properties due to actions on Kv7 channels, G-protein-regulated inwardly rectifying K channels and γ-aminobutyric acid type A receptors leading to the suppression of over excitability of neuronal and non-neuronal cells. Consequently flupirtine has demonstrated efficacy consistent with use as an analgesic, an anticonvulsant, a neuroprotectant, skeletal and smooth muscle relaxant, in treatment of auditory and visual disorders, and treatment of memory and cognitive impairment. Flupirtine is providing important information and clues regarding novel mechanistic approaches to the treatment of a range of clinical conditions involving hyper-excitability of cells.